Puma Biotechnology, Inc. $PBYI Shares Sold by Globeflex Capital L P

Posted by Brenda Bartman on Jul 23rd, 2026

Globeflex Capital L P decreased its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI – Free Report) by 22.7% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 349,651 shares of the biopharmaceutical company’s stock after selling 102,955 shares during the quarter. Globeflex Capital L P owned about 0.69% of Puma Biotechnology worth $2,234,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP grew its holdings in Puma Biotechnology by 7.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,436,106 shares of the biopharmaceutical company’s stock valued at $9,175,000 after buying an additional 96,503 shares in the last quarter. O Shaughnessy Asset Management LLC raised its holdings in shares of Puma Biotechnology by 35.3% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 1,120,329 shares of the biopharmaceutical company’s stock worth $6,666,000 after acquiring an additional 292,108 shares during the period. Geode Capital Management LLC raised its holdings in shares of Puma Biotechnology by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 994,345 shares of the biopharmaceutical company’s stock worth $5,917,000 after acquiring an additional 10,823 shares during the period. Russell Investments Group Ltd. boosted its position in shares of Puma Biotechnology by 4,823,365.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 964,693 shares of the biopharmaceutical company’s stock valued at $5,123,000 after acquiring an additional 964,673 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Puma Biotechnology by 17.2% during the 4th quarter. State Street Corp now owns 877,077 shares of the biopharmaceutical company’s stock valued at $5,219,000 after acquiring an additional 128,419 shares during the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

Insider Buying and Selling

In other news, Director Jay M. Moyes sold 22,000 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $7.22, for a total value of $158,840.00. Following the transaction, the director directly owned 58,322 shares in the company, valued at approximately $421,084.84. This represents a 27.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Allison Dorval sold 11,610 shares of the stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $7.20, for a total transaction of $83,592.00. Following the transaction, the director directly owned 90,780 shares of the company’s stock, valued at $653,616. The trade was a 11.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 132,028 shares of company stock valued at $1,006,711 over the last three months. Company insiders own 22.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on PBYI shares. Wall Street Zen cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 16th. Weiss Ratings lowered shares of Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Puma Biotechnology has a consensus rating of “Hold”.

View Our Latest Report on Puma Biotechnology

Puma Biotechnology Stock Down 8.3%

NASDAQ:PBYI opened at $7.87 on Thursday. Puma Biotechnology, Inc. has a 52 week low of $3.03 and a 52 week high of $8.75. The company has a market capitalization of $400.58 million, a P/E ratio of 16.40 and a beta of 1.20. The stock’s fifty day moving average is $7.58 and its two-hundred day moving average is $7.03.

Puma Biotechnology (NASDAQ:PBYI – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.09. The business had revenue of $44.81 million for the quarter, compared to analyst estimates of $42.00 million. Puma Biotechnology had a return on equity of 20.30% and a net margin of 10.69%. Sell-side analysts anticipate that Puma Biotechnology, Inc. will post 0.28 earnings per share for the current fiscal year.

Puma Biotechnology Company Profile

(Free Report)

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.